四面体框架核酸通过 PI3K/AKT/mTOR 信号通路抑制缺血性视网膜病的病理性新生血管形成和血管闭塞,Cell Proliferation

当前位置： X-MOL 学术 › Cell Prolif. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

四面体框架核酸通过 PI3K/AKT/mTOR 信号通路抑制缺血性视网膜病的病理性新生血管形成和血管闭塞
Cell Proliferation ( IF 5.9 ) Pub Date : 2023-01-24 , DOI: 10.1111/cpr.13407
Xiaodi Zhou ₁ , Yanting Lai ₁ , Xiaoxiao Xu ₂ , Qiong Wang ₁ , Limei Sun ₁ , Limei Chen ₁ , Jiajie Li ₃ , Rong Li ₂ , Delun Luo ₂ , Yunfeng Lin ₃ , Xiaoyan Ding ₁

Affiliation

本研究旨在探讨四面体框架核酸（tFNA）这种具有优异生物相容性和优越内吞能力的新型自组装纳米材料在抑制病理性视网膜新生血管（RNV）以及改善视网膜新生血管中的作用和分子机制。缺血性视网膜病变中的血管闭塞（VO）。tFNA 由四个单链 DNA (ssDNA) 合成。进行细胞增殖、伤口愈合和管形成测定，以探索体外细胞血管生成功能。通过体内氧诱导视网膜病变 (OIR) 模型探讨了 tFNA 在减少血管生成和抑制 VO 方面的作用。在体外，tFNA 能够进入内皮细胞 (EC)，在缺氧条件下抑制细胞增殖、管形成和迁移。在体内，tFNA 通过 PI3K/AKT/mTOR/S6K 通路成功降低 OIR 模型中的 RNV 并抑制 VO，而血管内皮生长因子融合蛋白 Aflibercept 可以降低 RNV 但不能抑制 VO。这项研究为进一步了解 RNV 提供了理论基础，并表明 tFNA 可能是治疗导致失明的 RNV 的新的有前景的候选药物。

"点击查看英文标题和摘要"

Tetrahedral framework nucleic acids inhibit pathological neovascularization and vaso-obliteration in ischaemic retinopathy via PI3K/AKT/mTOR signalling pathway

This study aimed to explore the effect and the molecular mechanism of tetrahedral framework nucleic acids (tFNAs), a novel self-assembled nanomaterial with excellent biocompatibility and superior endocytosis ability, in inhibition of pathological retinal neovascularization (RNV) and more importantly, in amelioration of vaso-obliteration (VO) in ischaemic retinopathy. tFNAs were synthesized from four single-stranded DNAs (ssDNAs). Cell proliferation, wound healing and tube formation assays were performed to explore cellular angiogenic functions in vitro. The effects of tFNAs on reducing angiogenesis and inhibiting VO were explored by oxygen-induced retinopathy (OIR) model in vivo. In vitro, tFNAs were capable to enter endothelial cells (ECs), inhibit cell proliferation, tube formation and migration under hypoxic conditions. In vivo, tFNAs successfully reduce RNV and inhibit VO in OIR model via the PI3K/AKT/mTOR/S6K pathway, while vascular endothelial growth factor fusion protein, Aflibercept, could reduce RNV but not inhibit VO. This study provides a theoretical basis for the further understanding of RNV and suggests that tFNAs might be a novel promising candidate for the treatment of blind-causing RNV.

更新日期：2023-01-24

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南